12 articles tagged #weight-loss.
For the first time ever, consumers can choose between two FDA-approved GLP-1 pills for weight loss. Foundayo (orforglipron) and oral Wegovy (semaglutide) take fundamentally different approaches — here's how they compare on efficacy, dosing convenience, side effects, and price.
Ozempic and Wegovy contain the exact same active ingredient — semaglutide — but they're approved for different conditions, come in different doses, and are priced differently. Here's what actually matters when choosing between them.
Medicare will cover Wegovy and Zepbound for weight loss starting July 1, 2026, at a flat $50/month copay. Here is everything you need to know about eligibility, the prior authorization process, how to prepare, and what happens when the BALANCE Model launches in January 2027.
Two of the biggest telehealth platforms now offer branded Wegovy and GLP-1 programs. We compare Ro and Hims on pricing, medications, insurance, clinical support, and what actually changed after the Novo Nordisk lawsuit.
Beyond Wegovy and Zepbound, a new generation of obesity drugs is racing toward FDA approval. CagriSema, MariTide (monthly injection), survodutide, and more — here's every drug in the pipeline with clinical data.
The FDA just approved Eli Lilly's Foundayo (orforglipron) — the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.
Retatrutide achieved 28.7% weight loss in Phase 3 trials — nearly double semaglutide. Here's everything known about Eli Lilly's next-generation triple-agonist, from clinical data to expected approval timeline.
Medicare will begin covering GLP-1 weight loss medications at $50/month starting July 2026. Here's who qualifies, how it works, and what comes next.
Starting a GLP-1? Here's a realistic week-by-week breakdown of what happens — from the initial consultation through your first dose escalation.
From $25/month with a savings card to $1,350 list price — the GLP-1 pricing landscape is confusing. Here's every option with real numbers.
The FDA ended the semaglutide shortage in February 2025, upending the compounded GLP-1 market. Here's what changed, what's legal, and how to choose.
Everything you need to know about GLP-1 receptor agonists — how they work, what the clinical trials show, side effects, eligibility, and how to choose a provider.